Neurogene Inc. financial data

Symbol
NGNE on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1956% % 84%
Debt-to-equity 8% % -52%
Return On Equity -30% % -15%
Return On Assets -28% % -25%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 15,489,800 shares 4.3%
Common Stock, Shares, Outstanding 14,775,285 shares 14%
Entity Public Float $375,985,920 USD 1027%
Common Stock, Value, Issued $0 USD
Weighted Average Number of Shares Outstanding, Basic 21,168,431 shares 25%
Weighted Average Number of Shares Outstanding, Diluted 21,168,431 shares 25%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD
Research and Development Expense $69,714,000 USD 21%
General and Administrative Expense $27,596,000 USD 45%
Operating Income (Loss) $97,310,000 USD -28%
Net Income (Loss) Attributable to Parent $85,130,000 USD -103%
Earnings Per Share, Basic -4 USD/shares -117%
Earnings Per Share, Diluted -4 USD/shares -1077%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $71,005,000 USD 6.6%
Cash, Cash Equivalents, and Short-term Investments $312,400,000 USD
Other Assets, Current $208,000 USD -87%
Assets, Current $270,519,000 USD 88%
Property, Plant and Equipment, Net $13,484,000 USD -16%
Operating Lease, Right-of-Use Asset $2,394,000 USD -25%
Other Assets, Noncurrent $1,063,000 USD 35%
Assets $287,832,000 USD 75%
Accounts Payable, Current $1,544,000 USD -8.3%
Employee-related Liabilities, Current $3,869,000 USD 13%
Accrued Liabilities, Current $9,424,000 USD -9.7%
Liabilities, Current $14,710,000 USD -6.9%
Operating Lease, Liability, Noncurrent $7,097,000 USD -30%
Other Liabilities, Noncurrent $51,000 USD 0%
Liabilities $22,292,000 USD -17%
Retained Earnings (Accumulated Deficit) $327,914,000 USD -35%
Stockholders' Equity Attributable to Parent $265,540,000 USD 93%
Liabilities and Equity $287,832,000 USD 75%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $20,774,000 USD 4%
Net Cash Provided by (Used in) Financing Activities $4,000 USD
Net Cash Provided by (Used in) Investing Activities $45,045,000 USD -250%
Common Stock, Shares Authorized 450,000,000 shares 0%
Common Stock, Shares, Issued 14,775,285 shares 14%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $65,815,000 USD -3837%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $71,344,000 USD 6.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities $2,000 USD -33%
Deferred Tax Assets, Valuation Allowance $114,972,000 USD 16%
Deferred Tax Assets, Gross $115,686,000 USD 16%
Operating Lease, Liability $12,348,000 USD -17%
Payments to Acquire Property, Plant, and Equipment $780,000 USD 1100%
Lessee, Operating Lease, Liability, to be Paid $14,829,000 USD -20%
Property, Plant and Equipment, Gross $26,913,000 USD 1.7%
Operating Lease, Liability, Current $3,073,000 USD 7.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,695,000 USD -6.8%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,987,000 USD 3.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,481,000 USD -34%
Lessee, Operating Lease, Liability, to be Paid, Year Three $3,239,000 USD -12%
Deferred Tax Assets, Operating Loss Carryforwards $69,308,000 USD 15%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50,000,000 shares 0%
Unrecognized Tax Benefits $3,364,000 USD 29%
Lessee, Operating Lease, Liability, to be Paid, Year Four $3,294,000 USD 1.8%
Operating Lease, Payments $1,306,000 USD
Additional Paid in Capital $593,454,000 USD 56%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $3,130,000 USD -4.1%
Deferred Tax Assets, Net of Valuation Allowance $714,000 USD -25%
Share-based Payment Arrangement, Expense $13,308,000 USD 115%
Interest Expense $3,000 USD 50%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%